Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CanadaBis CapitalTSXV:CANB Debt-to-Equity is 0.98 as of Oct. 2025, which is 38% below its 10-year median of 1.58. The stock has 6 warning signs investors should review. Among 811 Drug Manufacturers companies, CanadaBis Capital ranks worse than 85.08% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for CanadaBis Capital's Debt-to-Equity or its related term are showing as below:
TSXV:CANB'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.25 Med: 1.58 Max: 5.59
Current: 0.98
During the past 10 years, the highest Debt-to-Equity Ratio of CanadaBis Capital was 5.59. The lowest was 0.25. And the median was 1.58.
TSXV:CANB's Debt-to-Equity is ranked worse than 85.08% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs TSXV:CANB: 0.98
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
CanadaBis Capital Debt-to-Equity Related Terms
CanadaBis Capital Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for CanadaBis Capital's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:CANB vs GCAN, STEK, GRPS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CanadaBis Capital's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanadaBis Capital Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanadaBis Capital's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where CanadaBis Capital's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CanadaBis Capital (TSXV:CANB) has a Debt-to-Equity of 0.98 as of Oct. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on CanadaBis Capital and its competitors. This is 38% below median its historical median of 1.58. Over the past decade, CanadaBis Capital's Debt-to-Equity has ranged from 0.25 to 5.59. According to the industry distribution chart, CanadaBis Capital ranks #690 out of 811 companies in the Drug Manufacturers industry, placing it in the top 85.1%.
Is CanadaBis Capital's Debt-to-Equity too high?
CanadaBis Capital's current Debt-to-Equity of 0.98 is 38% below median its 10-year median of 1.58. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 5.59. The Drug Manufacturers industry median Debt-to-Equity is 0.28. CanadaBis Capital's value of 0.98 is 250% above this industry median. Based on the distribution chart, CanadaBis Capital ranks #690 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does CanadaBis Capital's Debt-to-Equity compare to GCAN and STEK?
According to the Drug Manufacturers industry distribution chart, CanadaBis Capital ranks #690 out of 811 companies for Debt-to-Equity. This places CanadaBis Capital in the lower half of its industry. The industry median Debt-to-Equity is 0.28. CanadaBis Capital's value of 0.98 is 250% above this benchmark. Historically, CanadaBis Capital's own Debt-to-Equity has ranged from 0.25 to 5.59 over the past decade. While the company's 10-year median is 1.58 vs. the industry median of 0.28, CanadaBis Capital has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CanadaBis Capital's current Debt-to-Equity of 0.98 is 250% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on CanadaBis Capital and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanadaBis Capital's current Debt-to-Equity is 0.98, which is 38% below median its own 10-year median of 1.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanadaBis Capital stock overvalued right now?
CanadaBis Capital (TSXV:CANB) has a current Debt-to-Equity of 0.98. The stock's GF Value™ is C$0.07, compared to a current price of C$0.02 — trading 78.6% below its estimated fair value. The current Debt-to-Equity is 0.98, which is 38% below median its 10-year median of 1.58 and 250% above the Drug Manufacturers industry median of 0.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For CanadaBis Capital (TSXV:CANB), the current Debt-to-Equity is 0.98 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CanadaBis Capital Inc is a vertically integrated cannabis company. The firm engages in the production and sale of recreational cannabis. Its product line consists of Stigma Roots. It operates in three segments: wholesale, retail, and extract. The wholesale segment cultivates and distributes cannabis and cannabis products to and through, provincial liquor and cannabis boards. Retail segment involves sale of cannabis and cannabis-related products to end consumers on-premises owned and operated by the Company. Extract segment provides cannabinoid extraction services to other licensed producers. The company generates maximum of its revenue from Extract Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:CANB has been successfully added to your 
